Founded by entrepreneur Claudio D’Angelo, Spex Capital has closed 10 investments in this space, as it seeks to broaden its investment into founders with the vision to back the innovators in healthcare. 

Through an exclusive two-year partnership with MedCity, the life sciences cluster organisation for London, Spex Capital uses connections to the National Health Service in England and extensive reach across the wider ecosystem. Joint activities include an international investment programme that contributes to the flow of around 1,000 healthcare companies developing breakthrough technologies every year.

“Even before Covid-19, the drive for countries to make better use of digital technology in healthcare had already begun,” D’Angelo said.

Spex Capital is also appointing Brent Stackhouse, the managing director of Mount Sinai Ventures, to join the team. Stackhouse has invested in the US healthcare system and brings international experience to the business.

“We now have an opportunity to acquire high quality assets at discounted valuations. We look forward to shaping the global healthcare ecosystem by helping innovators in developing groundbreaking technologies and solutions to overcome healthcare challenges worldwide,” Stackhouse said.

Spex Capital was founded in 2021. The new fund, which is an investment compartment of Spex Venture Fund, S.C.A. SICAV-RAIF, is incorporated in Luxembourg.

The fund is supported and serviced by top tier institutions and market specialists such as Crédit Suisse (independent administrator, registrar, transfer agent and depositary bank), One Fund Management (third-party alternative investment fund manager), Stibbe Avocats (legal counsel) and Deloitte Audit (statutory auditor).